The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

Mon, 09th Dec 2019 11:23

(Alliance News) - Open Orphan PLC and hVIVO PLC on Monday said they have agreed terms on a reverse takeover, which would value the latter at GBP13.0 million.

Under the terms of the agreement, hVIVO shareholders will receive 2.47 new Open Orphan shares per hVIVO share. The deal values hVIVO shares at 15.56 pence each, a 34% premium to the clinical development services company's closing price of 11.62p on Friday.

hVIVO shares were trading 3.2% higher at 12.00p each in London on Monday morning. Drug consulting firm Open Orphan, also listed in London, was 13% lower at 5.00p each.

As the tie-up is deemed a reverse acquisition, Open Orphan needs the approval of its shareholders at a January 6 general meeting to confirm the deal.

Open Orphan said it expects to issue 205.5 million shares under the terms of the merger, with hVIVO shareholders owning just shy of 45% of the enlarged firm.

Open Orphan said: "Open Orphan and hVIVO are AIM-quoted groups that share a similar vision for the future of European Clinical Research Organisations and an entrepreneurial approach to developing further their business through a focus on operational efficiency, organic growth and targeted acquisitions to expand their geographic and service capabilities.

"The Open Orphan directors and the hVIVO directors believe that the combination of the businesses will result in synergies across the enlarged group with each business providing complementary services with limited overlap in existing capabilities and customers."

hVIVO's directors, which have backed the offer, hold a 0.3% stake in the company. Open Orphan shareholders, with an interest totalling roughly 30% of the firm, have also supported the tie-up.

Open Orphan Chief Executive Cathal Friel said: "The merger of Open Orphan and hVIVO is a key milestone in the execution of our strategy to become a larger-scale specialist pharma services business and in complementary segments where specialist skills and know-how command higher margins.

"The merger allows the combined business to maximise shareholder value through delivering cost and revenue synergies across the businesses and one that is better positioned to consistently capture greater market share as part of a properly profitable business with losses confined to the past."

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
11 May 2020 12:03

UK TRADING UPDATE SUMMARY: Blencowe And BlueRock Recommence Operations

UK TRADING UPDATE SUMMARY: Blencowe And BlueRock Recommence Operations

Read more
11 May 2020 09:06

Open Orphan inks contract with Quotient on Covid-19 antibody testing

(Sharecast News) - Pharmaceutical services company Open Orphan's hVIVO subsidiary has entered into an exclusive contract with Quotient to support Covid-19 antibody testing in the UK.

Read more
4 May 2020 16:21

Open Orphan signs ?3.5m deal with US biotech firm

(Sharecast News) - Pharmaceutical services company Open Orphan announced the signing of a new contract with an unnamed US biotechnology company on Monday, for the provision of a respiratory syncytial virus (RSV) human challenge study.

Read more
4 May 2020 14:35

Open Orphan CEO Steps Down; Inks New Challenge Study Contract

Open Orphan CEO Steps Down; Inks New Challenge Study Contract

Read more
23 Apr 2020 15:40

UK TRADING UPDATE SUMMARY: Braemar Says Oil Tankers Wanted For Storage

UK TRADING UPDATE SUMMARY: Braemar Says Oil Tankers Wanted For Storage

Read more
23 Apr 2020 10:21

Open Orphan begins testing of Covid-19 anti-viral treatment

(Sharecast News) - Pharmaceutical services company Open Orphan said it had started testing an anti-viral drug to treat Covid-19 on behalf of its client Nearmedic International.

Read more
10 Mar 2020 14:48

Open Orphan Notes Publication Of FLU-v Vaccine Study In Journal

Open Orphan Notes Publication Of FLU-v Vaccine Study In Journal

Read more
9 Mar 2020 14:17

Open Orphan Starts On Coronavirus Challenge Study Model

Open Orphan Starts On Coronavirus Challenge Study Model

Read more
6 Mar 2020 15:23

Open Orphan agrees study with European biotech firm

(Sharecast News) - Orphan drugs-focussed pharmaceutical company Open Orphan announced the signing of a new contract with an unnamed European biotechnology firm for the provision of an RSV human challenge study.

Read more
6 Mar 2020 11:57

Open Orphan Inks New Virus Study Contract With Potential Follow-On

Open Orphan Inks New Virus Study Contract With Potential Follow-On

Read more
27 Feb 2020 17:56

EXECUTIVE CHANGE SUMMARY: Burford Capital Adds Independent Directors

EXECUTIVE CHANGE SUMMARY: Burford Capital Adds Independent Directors

Read more
13 Feb 2020 14:45

Open Orphan Appoints Interim CFO Leo Toole To Permanent Role

Open Orphan Appoints Interim CFO Leo Toole To Permanent Role

Read more
31 Jan 2020 15:39

Open Orphan raising at least ?5m for merger with hVIVO

(Sharecast News) - Pharmaceutical services company Open Orphan announced a fundraising to raise a minimum of £5m before expenses via a conditional placing of new ordinary shares on Friday, at a price of 6.1p each, to institutional and other investors.

Read more
31 Jan 2020 12:39

Open Orphan Raises GBP5.3 Million To Fund hVIVO Synergy Programme

Open Orphan Raises GBP5.3 Million To Fund hVIVO Synergy Programme

Read more
23 Jan 2020 18:32

Open Orphan In Talks With Investors Regarding GBP5 Million Placing

Open Orphan In Talks With Investors Regarding GBP5 Million Placing

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.